AXL and head and neck squamous cell carcinoma: Therefore, we hypothesize that RTK-AXL shedding products might be involved in the development of therapy resistance in GBM by an alternative pathway activation or induction of transcriptional effects, as it has been shown by McDaniel et al. and Hong et al. for head and neck squamous cell carcinoma [34,35].